N2038

Monoclonal Anti-NY-ESO-1 antibody produced in mouse

clone E978, purified from hybridoma cell culture

• Synonyme(s) : Anti-CTAG1, Anti-Cancer/Testis Antigen 1
• Numéro MDL: MFCD09265426
• Code UNSPSC : 12352203
• Nomenclature NACRES : NA.41

Propriétés

• Source biologique: mouse
• Niveau de qualité: 300
• Conjugué: unconjugated
• Forme d'anticorps: purified immunoglobulin
• Type de produit anticorps: primary antibodies
• Clone: E978, monoclonal
• Forme: buffered aqueous solution
• Poids mol.: antigen ~23 kDa
• Espèces réactives: human
• Conditionnement: antibody small pack of 25 μL
• Concentration: ~1 mg/mL
• Technique(s): immunohistochemistry: suitable; indirect ELISA: suitable; western blot: 1-2 μg/mL using SKMel-37 total cell extract
• Isotype: IgG1
• Conditions d'expédition: dry ice
• Température de stockage: −20°C
• Modification post-traductionnelle de la cible: unmodified
• Informations sur le gène: human ... CTAG1B(1485)

Description

Description générale

Monoclonal Anti-NY-ESO-1 (mouse IgG1 isotype) is derived from the hybridoma E978 produced by the fusion of mouse myeloma cells (SP2/0) and splenocytes from BALB/c mice immunized with human recombinant NY-ESO-1. The NY-ESO-1, also known as cancer/testis antigen 1 is expressed in normal testis and to a much lower extent in placenta, ovary and uterus.

Immunogène

recombinant human NY-ESO-1.

Application

Monoclonal Anti-NY-ESO-1 antibody produced in mouse has been used in enzyme linked immunosorbent assays (ELISA), immunoblotting and immunohistochemistry.

Monoclonal Anti-NY-ESO-1 is used as a probe to determine the presence and roles of Cancer/Testis Antigen 1 in humoral immune responses and a variety of cancers.

Actions biochimiques/physiologiques

Cancer/testis (CT) antigens are the protein products of genes that are activated in a wide variety of tumors and can elicit autologous cellular and humoral immune responses. Their normal expression is restricted to male germ cells in the testis and they are not expressed in adult somatic tissues. Therefore, CT antigens are promising candidates for cancer immunotherapy. Approximately 20 CT antigens or antigen families have been identified to date. NY-ESO-1 is a CT protein to which cell-mediated immune response has been demonstrated. It is highly expressed in various types of cancers. For example, patients with melanoma contain tumor-infiltrating lymphocytes cells (TILs) that recognized NY-ESO-1 protein. The expression of genes encoding CT antigens was examined in sporadic medullary thyroid carcinoma. The expression of NY-ESO-1 was found in 65 percent of the samples and correlated with tumor recurrence in primary MTC tumors. Furthermore, high frequency of expression was found in breast cancer especially in benign lesions and in multiple myeloma. Due to its wide expression in different cancers, NY-ESO-1 protein was used as a vaccine in cancer patients.

Forme physique

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Informations sur la sécurité

• Code de la classe de stockage: 10 - Combustible liquids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)